65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details
臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03601286 (ClinicalTrials.gov) | December 21, 2018 | 22/2/2018 | Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency | Phase I/II Study of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan | Severe Combined Immunodeficiency, X-Linked | Drug: Lentiviral vector transduced CD34+ cells | Great Ormond Street Hospital for Children NHS Foundation Trust | NULL | Recruiting | 8 Weeks | 5 Years | Male | 5 | Phase 1 | United Kingdom |
| 2 | NCT01381003 (ClinicalTrials.gov) | November 2011 | 23/6/2011 | Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD) | Phase I/II Gene Therapy Protocol for X-Linked Chronic Granulomatous Disease | Granulomatous Disease, Chronic, X-linked, Variant | Genetic: pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion | Great Ormond Street Hospital for Children NHS Foundation Trust | NULL | Withdrawn | N/A | 30 Years | Male | 0 | Phase 1/Phase 2 | United Kingdom |